Martin Dahl, PhD, of AnaptysBio discusses the findings and limitations of a study analyzing use of ANB032 in patients with atopic dermatitis (AD). Lawrence Eichenfield, MD, chief of pediatric and ...
Ruxolitinib cream for vitiligo showed 60% of patients maintained benefits post-treatment, with potential for skin repigmentation upon reinitiation. JNJ-2113 demonstrated significant efficacy in ...
The revision follows AnaptysBio's recent Phase 2b trial failure of ANB032 in atopic dermatitis (AD), which led to its removal from the sum-of-the-parts (SOTP) valuation of the company. The stock, ...
Analysts have set 12-month price targets for AnaptysBio, revealing an average target of $48.22, a high estimate of $90.00, ...
The failure of ANB032 in Phase 2B for atopic dermatitis has shifted focus to rosnilimab, which faces significant competition and uncertain prospects. Rosnilimab's upcoming Phase 2B results for ...
Zacks.com on MSN18d
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX GainsIt was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.
The revision follows AnaptysBio's recent Phase 2b trial failure of ANB032 in atopic dermatitis (AD), which led to its removal from the sum-of-the-parts (SOTP) valuation of the company. The stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback